Monday, May 1, 2017, Inc. (CIIX) Set to Capitalize on Meteoric Growth of CBD Market

The chemical in marijuana that causes euphoria is delta-9 tetrahydrocannabinol, or THC. There are also over 100 other cannabinoid chemicals in the plant, including cannabidiol (CBD), one of the main active chemical compounds found in marijuana. CBD doesn’t make people high, isn’t intoxicating or addictive, and is gaining widespread acceptance as a natural and effective medicinal treatment for multiple disorders. Both anecdotal evidence and pre-clinical research have pointed to CBD as having a broad range of beneficial therapeutic uses, including anti-seizure, antioxidant, neuro-protective, anti-inflammatory, analgesic, anti-tumor, anti-anxiety, and anti-psychotic properties. CBD oil has already been legalized in all 50 U.S. states and can be exported to over 40 countries, including China. With an annual growth rate of nearly 60 percent, CBD oil has become one of the fastest-growing market categories in the country. U.S.-based, Inc. (OTCQB: CIIX) is set to capitalize on this meteoric growth.

With long term focus on value-add opportunities, has consistently delivered a broad range of products, services, and information for the global Chinese speaking population since 1999. This specialized investment services company provides real-time market commentary, analysis, and education-related services in the Chinese language, and it offers several subscription-based services as well as consultation, advertising, and public relations services. After profiting from a successful investment in the marijuana market, the company recognized an immense opportunity and recently expanded into retail and online sales of CBD products. The company has a 100,000+ user base, a recognizable 18-year-old brand and a target market of nearly two billion Chinese-speaking people. is positioning to become the world’s leading Chinese medical marijuana company and to dominate this new market.

In January, the company launched the world’s first CBD health products online store in the Chinese language ( Traditional Chinese medicine embraces holistic, natural remedies, which suggests that online sales and future retail outlets could easily exceed expectations. In conjunction with these expectations, SeeThruEquity, a leading independent equity research firm, recently raised its price target for to $3.75 a share. With the stock currently trading at just over a dollar per share, could provide an exceptional opportunity to profit from the medical marijuana market and nearly two billion potential new customers.

For more information, visit the company’s website at

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at

The Quality Stocks Daily Blog

The Quality Stocks Daily Videos

The Quality Stocks “Ones to Watch”

Please see disclaimer on the QualityStocks website:

No comments: